Program News
News and stories about the UNC Lineberger Leukemia Oncology Program
-
Novel drug combination is safe and benefits people with acute myeloid leukemia who have a specific genetic profile
Joshua Zeidner, MD, and colleagues report that a combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia showed high rates of complete remission in an early-phase clinical trial.
-
Adaptive whole-genome sequencing could transform childhood leukemia diagnosis
UNC Lineberger researchers have demonstrated a faster, more cost-effective approach to analyzing the genetic makeup of pediatric acute leukemia. Determining a cancer’s genomic classification is critical to developing a more effective treatment plan tailored to a patient’s tumor.
-
New treatments offer promise to people with acute myeloid leukemia
Joshua Zeidner, MD, a hematologist/oncologist specializing in the management of acute leukemia, explains some of the advances in the treatment of acute myeloid leukemia (AML).
-
Nanotechnology offers lower cost, high accuracy approach to diagnosing leukemias in low resource countries
A newer, less expensive nanotechnology may make it possible to more accurately diagnose children with acute leukemia in lower income countries, according to findings by Thomas Alexander, MD, MPH, and colleagues.
-
Couple unified through cancer, caregiver struggles
When a significant other is diagnosed with cancer, it can be just as hard on the loved one as it is on the patient. However, Stephen and Jackie Alston found themselves experiencing both roles when they were each diagnosed with cancer years apart.
-
Student-athlete raising awareness, funds for other young people with cancer
Emily Grund, a member of the UNC-Chapel Hill diving team, found support from friends, family and UNC Lineberger programs after being diagnosed with acute promyelocytic leukemia, a rare form of cancer.
-
Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukemia
Josh Zeidner, MD, Jon Serody, MD, and colleagues report clinical trial outcomes that benefited patients with resistant or relapsed acute myeloid leukemia.
-
Early phase study finds combination therapy effective against difficult to treat leukemia and lymphoma
Thomas Alexander, MD, MPH, and colleagues published findings from a study that found pairing venetoclax with low-dose navitoclax and chemotherapy had promising efficacy in patients with difficult to treat leukemia and lymphoma.